ANGLE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.5 GBX | +3.57% |
|
+20.83% | +23.40% |
| 04-24 | No record close for FTSE 100; mixed trade in US | AN |
| 04-24 | No record close for FTSE 100; mixed trade in US | AN |
| Sales 2023 * | 2.08M 2.6M 3.55M | Sales 2024 * | 7.61M 9.51M 13M | Capitalization | 37.77M 47.18M 64.5M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -23.73M -32.45M | Net income 2024 * | -14M -17.49M -23.91M | EV / Sales 2023 * | 12.1 x |
| Net cash position 2023 * | 12.56M 15.69M 21.46M | Net cash position 2024 * | 1.6M 2M 2.74M | EV / Sales 2024 * | 4.75 x |
| P/E ratio 2023 * |
-1.92
x | P/E ratio 2024 * |
-2.56
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on ANGLE plc
More press releases
| 1 day | +3.57% | ||
| 1 week | +20.83% | ||
| Current month | +16.00% | ||
| 1 month | +18.37% | ||
| 3 months | -17.14% | ||
| 6 months | +23.40% | ||
| Current year | +23.40% |
1 week
12.00
17.63
1 month
11.2617.63
Current year
11.2637.40
1 year
9.0737.40
3 years
9.07163.75
5 years
9.07163.75
10 years
9.07163.75
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Brian Howlett
BRD | Director/Board Member | 80 | 13-01-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 14.5 | +3.57% | 1,310,616 |
| 24-04-25 | 14 | -9.68% | 2,201,112 |
| 24-04-24 | 15.5 | +26.53% | 12,615,900 |
| 24-04-23 | 12.25 | -2.00% | 553,192 |
| 24-04-22 | 12.5 | +4.17% | 1,029,292 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotes
ANGLE plc is a United Kingdom-based liquid biopsy company. The Company is engaged in the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy-non-invasive cancer diagnostics. Its platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplexed analysis of nucleic acids and proteins. Its Parsortix PC1 Clinical system captures and harvests circulating CTCs from metastatic breast cancer patients blood for subsequent, user-validated analysis. The Parsortix PC1 Clinical System is a liquid biopsy technology. Its labs in Guildford provide specialist CTC enrichment and analysis services to support translational research studies and pharmaceutical trials. It has developed the Parsortix system, including instruments and one-time use cassettes that can be sold to third-party laboratories for their use in research, pharmaceutical development, or clinical use.
Calendar
2024-06-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.145
GBP
Average target price
0.685
GBP
Spread / Average Target
+372.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.40% | 47.04M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- AGL Stock
